Albany, USA & Shanghai, China – March 26, 2026
Drug Farm announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational drug DF-003 into the Rare Disease Evidence Principles Process (RDEP), marking a significant regulatory milestone in the development of a first-in-class therapy for ROSAH syndrome, a rare and currently untreatable genetic disorder. The acceptance enables early and structured engagement with the FDA, supporting optimized clinical trial design, regulatory strategy, and evidence generation for rare disease drug development.
FDA RDEP Acceptance Strengthens Regulatory Pathway
The inclusion of DF-003 in the FDA Rare Disease Evidence Principles Process (RDEP) represents a critical step toward advancing therapies for rare diseases with limited treatment options. The RDEP initiative is designed to facilitate early dialogue between regulators and drug developers, enabling companies to align on clinical development strategies, regulatory expectations, and innovative evidence generation approaches.
For Drug Farm, this acceptance provides an opportunity to collaborate closely with the FDA on clinical trial methodologies tailored to small patient populations, a key challenge in rare disease research. Through the RDEP program, the company aims to develop efficient and scientifically robust pathways for demonstrating clinical benefit, potentially accelerating the drug’s progression toward regulatory submission. This milestone underscores the growing importance of adaptive regulatory frameworks in supporting innovation in rare disease therapeutics.
DF-003 Targets Rare Genetic Disorder with High Unmet Need
Advertisement
DF-003 is a novel, first-in-class ALPK1 inhibitor being developed to treat ROSAH syndrome, a rare autoinflammatory disease caused by gain-of-function mutations in the ALPK1 gene. The condition is characterized by retinal degeneration, optic nerve edema, systemic inflammation, and progressive vision loss, often beginning in childhood or early adulthood. Importantly, there are currently no approved therapies specifically indicated for ROSAH syndrome, highlighting a significant unmet medical need.
Preclinical studies have demonstrated promising efficacy of DF-003 in targeting disease mechanisms, with potential applications beyond ROSAH syndrome, including cardiovascular and renal diseases. The drug has successfully completed a Phase 1 clinical trial in healthy volunteers and is currently advancing in a Phase 1b trial involving patients with ROSAH syndrome, reflecting steady progress in early-stage clinical development.
Advancing Clinical Development and Rare Disease Innovation
Participation in the RDEP program is expected to play a pivotal role in shaping the future clinical development strategy for DF-003, particularly in designing trials that can effectively evaluate outcomes in ultra-rare patient populations. Drug Farm plans to leverage insights gained from FDA discussions to optimize trial endpoints, improve data generation strategies, and enhance regulatory readiness.
The development of DF-003 is supported by Drug Farm’s proprietary IDInVivo platform, which integrates genetics and artificial intelligence to identify and validate novel drug targets in living biological systems. This innovative approach enables the company to accelerate drug discovery and translational research, positioning DF-003 as part of a broader pipeline of first-in-class therapies targeting innate immunity and inflammatory diseases.
The FDA’s acceptance of DF-003 into RDEP highlights the increasing focus on rare disease innovation, regulatory collaboration, and patient-centric drug development. As regulatory agencies continue to adopt flexible frameworks to support therapies for underserved populations, programs like RDEP are expected to play a crucial role in accelerating access to life-changing treatments.
Overall, the advancement of DF-003 underscores the importance of early regulatory engagement, innovative clinical trial design, and targeted therapeutic development in addressing rare genetic diseases. With continued collaboration between Drug Farm and the FDA, DF-003 has the potential to emerge as a breakthrough therapy for ROSAH syndrome, offering hope to patients who currently lack effective treatment options and reinforcing the role of precision medicine in rare disease management.
Source: Drug Farm press release
